The Director, HCP Marketing, Medical Education, & KOL Strategy, Alzheimer's Disease Psychosis (ADP) will be responsible for developing and executing the U.S. KOL engagement strategy, medical education programming, peer-to-peer promotional activities, and congress commercial strategy for the anticipated launch of ADP, a potential first-in-class, first-approved treatment for AD psychosis and BMS's inaugural commercial entry into Alzheimer's disease. In partnership with Medical and the Regional Marketing Team, this role will be critical in identifying and activating KOLs, owning the annual congress strategy and execution, developing and managing peer-to-peer and speaker bureau programs, and building the operational infrastructure for KOL engagement across psychiatry, neurology, geriatrics, geriatric psychiatry, primary care, and LTC settings.